ACM
COGT icon

Aster Capital Management’s Cogent Biosciences COGT Stock Holding History

Aster Capital Management’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-409
Closed -$2.45K – 918
2026
Q1 		$2.45K Buy
+409
New +$15.1K ﹤0.01% 747
2025
Q2 		– Sell
-2,061
Closed -$15.5K – 1124
2025
Q1 		$15.5K Buy
2,061
+1,466
+246% +$11.5K ﹤0.01% 1013
2024
Q4 		$4.64K Buy
595
+482
+427% +$4.8K ﹤0.01% 870
2024
Q3 		$1.22K Buy
+113
New +$1.1K ﹤0.01% 1005

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Aster Capital Management's COGT Position: Q2 2026 in Review

Aster Capital Management sold out of Cogent Biosciences (COGT) in Q2 2026, closing a stake of 409 shares — an estimated $2.45K sold.

Aster Capital Management first reported a position in COGT in Q3 2024 and held it in 4 quarters. The position peaked at $15.5K in Q1 2025. 323 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • Aster Capital Management reported no remaining Cogent Biosciences position as of Q2 2026 after selling out during the quarter.
  • Aster Capital Management sold 409 Cogent Biosciences shares in Q2 2026, an estimated $2.45K.
  • Aster Capital Management first reported a position in Cogent Biosciences in Q3 2024 and held it in 4 quarters.
  • Aster Capital Management's Cogent Biosciences position peaked at $15.5K in Q1 2025.
  • 323 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Aster Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.